Artisan Partners Limited Partnership Biocryst Pharmaceuticals Inc Transaction History

Artisan Partners Limited Partnership

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$7.94 - $11.84 $321,593 - $479,555	-40,503 Reduced 1.41%	2,837,924 $23.7 Million
Q4 2022 Feb 10, 2023	BUY	$10.5 - $14.2 $2.4 Million - $3.25 Million	228,811 Added 8.64%	2,878,427 $33 Million
Q3 2022 Nov 10, 2022	SELL	$10.79 - $14.81 $2.89 Million - $3.96 Million	-267,593 Reduced 9.17%	2,649,616 $33.4 Million
Q2 2022 Aug 12, 2022	BUY	$7.89 - $17.88 $598,093 - $1.36 Million	75,804 Added 2.67%	2,917,209 $30.9 Million
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $2,023 - $3,458	175 Added 0.01%	2,841,405 $46.2 Million
Q4 2021 Feb 11, 2022	SELL	$11.18 - $15.46 $113,521 - $156,980	-10,154 Reduced 0.36%	2,841,230 $39.4 Million
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $4.15 Million - $5.16 Million	-292,101 Reduced 9.29%	2,851,384 $41 Million
Q2 2021 Aug 12, 2021	BUY	$9.5 - $17.24 $1.12 Million - $2.03 Million	117,879 Added 3.9%	3,143,485 $49.7 Million
Q1 2021 May 11, 2021	BUY	$7.37 - $13.61 $22.3 Million - $41.2 Million	3,025,606 New	3,025,606 $30.8 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Artisan Partners Limited Partnership with notifications on news.